Arcede Pharma is in full swing with the preparations for clinical studies with drug candidate RCD405. CEO Mia Lundblad has announced that she will leave her position for a more research-oriented role outside the company. Lundblad will continue as CEO until the beginning of February, when the company’s CFO Erik Magnusson will take over as acting CEO.
Arcede Pharma is developing drug candidate RCD405, focused on the treatment of chronic obstructive pulmonary disease (COPD). The candidate has a dual mechanism of action that is both bronchodilatory and anti-inflammatory, which opens up the possibility of not only treating the symptoms but also influencing the underlying causes of the disease.
After completing toxicology studies with promising results, Arcede Pharma is now preparing for clinical phase I studies, planned to start in the latter part of 2024.
CEO Mia Lundblad resigns
The company’s CEO Mia Lundblad has now announced that she will resign, as she has been offered a more research-oriented position outside the company, a position she has been unable to refuse. The board of directors has therefore decided to appoint the current CFO Erik Magnusson as acting CEO as of 1 February 2024, while the chairman of the board, Ingemar Kihlström, will take on the role of executive chairman.
“RCD405 is an extremely exciting project with great potential, but I choose to leave in order to be able to focus more on the actual research and drug development role, which I have greater knowledge and awareness of”, writes Mia Lundblad in a press release.
Chairman of the board Ingemar Kihlström comments on Lundblad’s resignation: “During her time as CEO, Mia Lundblad has carried out many valuable tasks with the development of RCD405, including ensuring that the preclinical documentation prior to the start of phase I is completed, as well as establishing external collaborations with, for example, KI and Lund University to understand the pharmacological mechanism of action.”
Kihlström further comments on the appointment of Erik Magnusson as acting CEO: “Erik has extensive knowledge of life science for more than 25 years, from both large and small companies. He has a great capacity for work and I warmly welcome him to this assignment.”The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.